These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. The effect of isocarboxazid on platelet MAO activity. Davidson J; White H Biol Psychiatry; 1983 Sep; 18(9):1075-9. PubMed ID: 6640004 [No Abstract] [Full Text] [Related]
4. Side effects of isocarboxazid. Zisook S J Clin Psychiatry; 1984 Jul; 45(7 Pt 2):53-8. PubMed ID: 6376485 [TBL] [Abstract][Full Text] [Related]
5. The response of depressed inpatients to isocarboxazid. Davidson J; Lipper S; Pelton S; Miller RD; Hammett EB; Mahorney S; Varia IM J Clin Psychopharmacol; 1988 Apr; 8(2):100-7. PubMed ID: 3372704 [TBL] [Abstract][Full Text] [Related]
6. MAO inhibitor therapy in trichotillomania associated with depression: case report. Krishnan RR; Davidson J; Miller R J Clin Psychiatry; 1984 Jun; 45(6):267-8. PubMed ID: 6725219 [TBL] [Abstract][Full Text] [Related]
7. MAO inhibition and clinical response in depressed patients treated with phenelzine. Bresnahan DB; Pandey GN; Janicak PG; Sharma R; Boshes RA; Chang SS; Gierl BL; Davis JM J Clin Psychiatry; 1990 Feb; 51(2):47-50. PubMed ID: 2298705 [TBL] [Abstract][Full Text] [Related]
8. High initial nortriptyline doses in the treatment of depression. Warner MD; Griffin M; Peabody CA J Clin Psychiatry; 1993 Feb; 54(2):67-9. PubMed ID: 8444823 [TBL] [Abstract][Full Text] [Related]
9. Relapse, side effects, and monoamine oxidase inhibition during long term use of isocarboxazid: a case report. Davidson J; Sullivan JL J Clin Psychopharmacol; 1983 Feb; 3(1):42-3. PubMed ID: 6833523 [No Abstract] [Full Text] [Related]
10. Resistant geriatric depressions and therapeutic response to monoamine oxidase inhibitors. Georgotas A; Friedman E; McCarthy M; Mann J; Krakowski M; Siegel R; Ferris S Biol Psychiatry; 1983 Feb; 18(2):195-205. PubMed ID: 6830930 [TBL] [Abstract][Full Text] [Related]
11. Gepirone extended-release treatment of anxious depression: evidence from a retrospective subgroup analysis in patients with major depressive disorder. Alpert JE; Franznick DA; Hollander SB; Fava M J Clin Psychiatry; 2004 Aug; 65(8):1069-75. PubMed ID: 15323591 [TBL] [Abstract][Full Text] [Related]
12. An evaluation of two doses of isocarboxazid in depression. Davidson J; Miller R; Turnbull CD; Belyea M; Strickland R J Affect Disord; 1984 Apr; 6(2):201-7. PubMed ID: 6233352 [TBL] [Abstract][Full Text] [Related]
14. The effect of nefazodone on comorbid anxiety symptoms associated with depression: experience in family practice and psychiatric outpatient settings. Zajecka JM J Clin Psychiatry; 1996; 57 Suppl 2():10-4. PubMed ID: 8626357 [TBL] [Abstract][Full Text] [Related]
15. Affective and anxiety comorbidity in post-traumatic stress disorder treatment trials of sertraline. Brady KT; Clary CM Compr Psychiatry; 2003; 44(5):360-9. PubMed ID: 14505296 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial. Rynn M; Russell J; Erickson J; Detke MJ; Ball S; Dinkel J; Rickels K; Raskin J Depress Anxiety; 2008; 25(3):182-9. PubMed ID: 17311303 [TBL] [Abstract][Full Text] [Related]
17. Loss of appetite and weight associated with the monoamine oxidase inhibitor isocarboxazid. Davidson J; Turnbull C J Clin Psychopharmacol; 1982 Aug; 2(4):263-6. PubMed ID: 7119133 [No Abstract] [Full Text] [Related]